Searched over 200M research papers
10 papers analyzed
These studies suggest that nicotinamide mononucleotide (NMN) boosts NAD+ levels, improves cognitive function, promotes anti-aging effects, and has potential therapeutic applications in various diseases.
19 papers analyzed
Nicotinamide mononucleotide (NMN) is a crucial intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for various cellular processes. NMN is converted into NAD+, which plays a pivotal role in metabolism, DNA repair, gene expression, and stress responses . The biosynthesis of NMN can occur through the salvage pathway using nicotinamide or via phosphorylation of nicotinamide riboside.
Research has shown that NMN supplementation can significantly increase NAD+ levels, which tend to decline with age. This increase in NAD+ has been linked to various anti-aging benefits. For instance, long-term NMN administration in mice has been shown to mitigate age-associated physiological decline, enhance energy metabolism, improve insulin sensitivity, and promote physical activity without any obvious toxicity. Additionally, NMN has been found to improve mitochondrial function and reduce oxidative stress, further contributing to its anti-aging effects .
NMN also plays a critical role in maintaining cognitive and vascular health. In aged mice, NMN supplementation has been shown to rescue cerebromicrovascular endothelial function and improve neurovascular coupling responses, which are essential for cognitive function. This is achieved through the enhancement of endothelial nitric oxide-mediated vasodilation and the reduction of oxidative stress. Moreover, NMN treatment has been associated with an anti-aging miRNA expression profile in the aorta, predicting epigenetic rejuvenation and anti-atherogenic effects.
NMN has demonstrated potential in ameliorating various age-related diseases. In animal models, NMN administration has been shown to improve conditions such as obesity, diabetes, heart failure, and kidney failure by boosting NAD+ levels and enhancing metabolic functions . The vasoprotective effects of NMN, including improved endothelium-dependent vasodilation and reduced oxidative stress, further highlight its therapeutic potential in cardiovascular diseases.
Interestingly, high-dose NMN has been found to suppress lung adenocarcinoma growth by promoting ferroptosis through the NAM-mediated SIRT1–AMPK–ACC signaling pathway. This suggests that NMN can influence cancer cell metabolism and offers a new perspective on its use in clinical cancer therapy.
NMN has also been shown to maintain intestinal homeostasis by regulating gut microbiota. Long-term NMN treatment increases the abundance of beneficial bacteria and decreases harmful bacteria, thereby improving gut health. This modulation of gut microbiota is associated with enhanced intestinal barrier function, reduced mucosal permeability, and increased expression of tight junction proteins.
While most of the research on NMN has been conducted in animal models, initial human trials have shown promising results. A placebo-controlled, randomized trial demonstrated that oral NMN supplementation is safe and effectively increases NAD+ levels in healthy subjects without causing any adverse effects. However, more extensive clinical trials are needed to fully understand the long-term safety and efficacy of NMN supplementation in humans.
Nicotinamide mononucleotide (NMN) is a potent NAD+ precursor with significant potential in anti-aging, disease prevention, and treatment. Its ability to enhance NAD+ levels and improve various physiological functions makes it a promising candidate for therapeutic applications. However, further research, particularly in human clinical trials, is essential to fully realize its potential and ensure its safety for widespread use.
Most relevant research papers on this topic